Sarepta Therapeutics (SRPT) Long-Term Deferred Tax (2012 - 2013)
Sarepta Therapeutics (SRPT) posted quarterly Long-Term Deferred Tax of $133.6 million for Q4 2013, up 17.09% year-over-year from $114.1 million in Q4 2012, and up 17.09% quarter-over-quarter from $114.1 million in Q4 2012.
Powered by 
Analysis
Sarepta Therapeutics (SRPT) Long-Term Deferred Tax (2012 - 2013) Analysis & Trends
Sarepta Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $133.6 million for Q4 2013.
- In Q4 2013, Long-Term Deferred Tax rose 17.09% year-over-year to $133.6 million; the TTM figure through Dec 2013 stood at $133.6 million (up 17.09% YoY), while the FY2013 annual figure was $133.6 million, up 17.09% from the prior year.
- Long-Term Deferred Tax for Q4 2013 stood at $133.6 million, up from $114.1 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $133.6 million in Q4 2013, with the low at $114.1 million in Q4 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 2.36 Bn | 1.57 Bn | 251.87 Mn |